Dr. Firas Badin, MD
Claim this profileBaptist Health Lexington
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
23 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Firas Badin, MD is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Firas Badin, MD
Clinical Trial Related5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Firas Badin, MD has experience with
- Carboplatin
- Pembrolizumab
- Pemetrexed
- PD-1 Inhibitor
- Biospecimen Collection
- Crizotinib
Breakdown of trials Firas Badin, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Firas Badin, MD specialize in?
Firas Badin, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Firas Badin, MD currently recruiting for clinical trials?
Yes, Firas Badin, MD is currently recruiting for 3 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Firas Badin, MD has studied deeply?
Yes, Firas Badin, MD has studied treatments such as Carboplatin, Pembrolizumab, Pemetrexed.
What is the best way to schedule an appointment with Firas Badin, MD?
Apply for one of the trials that Firas Badin, MD is conducting.
What is the office address of Firas Badin, MD?
The office of Firas Badin, MD is located at: Baptist Health Lexington, Lexington, Kentucky 40503 United States. This is the address for their practice at the Baptist Health Lexington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.